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 Abstract 
Nanocapsules have become more popular as potential therapeutic agents in recent years. 
Though liposomes are the most popular and well-studied, nanocapsules made of peptides have 
their distinct advantages as the research behind them intensifies. Branched Amphiphilic Peptide 
Capsules (BAPCs) are a type of self-assembling nanocapsules that are made up of two similar 
branched, amphiphilic, chemically synthesized peptides. These peptides self-assemble into 
bilayer delimited capsules capable of encapsulating solutes and even small proteins in aqueous 
solution. Previous studies have shown that these nanocapsules are taken up by cells in culture 
without negative effects and can be given to an organism, distributed throughout the organism 
without cytotoxic effects, suggesting a possible future as a therapeutic nanoparticle. 
For use as a therapeutic system, the understanding of how these BAPCs behave in the 
presence of sodium and chloride, two very common biological ions, must be understood and 
characterized. Previously published work showed that the BAPC bilayer is semipermeable and 
excludes sodium and chloride ions. Current research has expanded on this. Besides being 
semipermeable, this bilayer is also a dynamic membrane that has the ability to expand and 
contract due to osmotic pressure from ions in solution. Eosin Y, an autoquenching dye, has been 
used for many of the studies to monitor the behavior and the amount of water within the BAPCs. 
Having insight into how the BAPCs change under physiological conditions is necessary if these 
nanoparticles are to be used in a clinical setting and may open doors to new uses. 
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Chapter 1 – Introduction and Background 
Self-Assembling Nanotechnology 
Nanotechnology and nanocapsules are those molecules or assembled particles that are 
less than 100 nm in diameter.1,2 Cells, being micrometers in diameter dwarf these nanoparticles. 
This small size allows them to be taken up by cells, but large enough to act as a drug delivery 
vehicle for therapeutic agents, suggesting future applications in basic research and clinical 
applications. Over the past 10 years, the field of nanotechnology and the use of nanoparticles and 
nanocapsules have become much more popular and a more attractive option for many 
applications. This can be seen by the increase in number of patents that have been issued for 
nanoparticles and nanocapsules, and the NIH has been increasing the funding for research being 
done with nanotechnology in the past 10 years.3,4  
Nanocapsules and nanoparticles come together via self-assembly, typically in aqueous 
solvents, and are held together non-covalently. Since their discovery, they have seen potential 
applications in material science, electronic devices, and chemical science with many of these 
nanoparticles designed with various clinical applications in mind.5 These could be used as a drug 
delivery system-especially for drugs that are hydrophobic or highly toxic, tissues or organ repair, 
cancers or other disease diagnostics, or vaccine delivery.6,7,8,9 With a maximum size of 6 nm for 
solutes that can pass through kidneys, nanocapsules can also be used to protect proteins, 
peptides, or other therapeutics from degradation or elimination from the body. This allows for 
increased circulation times thus giving the nanoparticles more time to reach the target cells and 
could even increase patient compliance. By increasing the stability and availability and 
decreasing degradation, the door could be opened to possible delivery mechanisms that were 
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previously not able to be accomplished, such as the effective oral delivery of protein and peptide 
drugs.10,11,12,13 
One of the most hopeful areas of nanotechnology is in the area of specialized cancer 
treatment and detection.6,7,14,15 Cancer is a leading cause of death, and the number of new cases is 
only expected to rise.16,17 Many of these nanocapsules can encapsulate poorly soluble or highly 
toxic drugs and deliver them to the desired cell for maximum therapeutic efficacy and decrease 
off-target side effects. Most currently approved nanocapsules and nanotechnologies used in 
therapeutics do not target specific cells, but they accumulate in tumor tissues due to the 
physiology of the tumors. The nanocapsules with a diameter as large as 200 nm can easily go 
through the leaky vessels around tumors, thereby passively targeting the malignant tissues.18 The 
hope and direction of development for these nanocapsules is for coating them with specific 
targeting molecules. By putting these specific epitopes, peptides, or small molecules on the 
surface of them either covalently-via disulfide bonds or NHS-linkage-or non-covalently-via 
electrostatic interactions or streptavidin-biotin conjugation-they can directly target the tumor 
cells for imaging or destruction.19,20 The future of nanotechnology is quite bright, and 
nanotechnology lends itself perfectly to be used in early and more accurate cancer detection-like 
use as adjuncts to CTs or X-rays, MRIs, PET scans, and ultrasound, better cancer treatment 
options, and cancer research along with use in many other areas of research, delivery, and 
therapeutics.1,4,12,21,22   
 
Liposomes 
Liposomes are the most commonly seen nanoparticle, and these were one of the first 
nanocarriers approved for medicinal use by the FDA in 1995.1,23,24 In the last thirty years, the 
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development and use of liposomes has sharply increased, especially in the field of 
pharmacology, and the use of liposomes approved for use in medicine has shown that they are 
effective.25 Composed of a lipid bilayer, liposomes can self-assemble within aqueous solvents, 
encapsulating various solvents and solutes within them or even within the bilayer.23,25 Using a 
liposome as a delivery vehicle for pharmacological agents has a number of advantages. First, 
liposomes are biodegradable and compatible with biological systems. Because of their 
compatibility with these systems, they can be predictably modified to retain or release cargo at 
certain conditions.26 Next, depending on how they are made, the sizes of the nanoparticles can 
also be tuned to a specific size and release the drug within it at certain conditions (e.g. 
temperature or pH).24  Moreover, when liposomes are used as part of a therapeutic drug, they can 
lengthen the time of circulation of the drug, aid in drug delivery to the inside of the cell, increase 
the efficacy of the drug, and have decreased side effects from the drug.23,27,28 Many of the drugs 
used are not readily soluble in solvents used for delivery of medications, so liposomes also 
solubilize these hard to dissolve molecules.27,29  
As mentioned previously, liposomes, like other nanoparticles, are being modified to 
contain specific molecules on the external surface of the capsule. Liposomes have been coated 
with polyethylene glycol (PEG). This coating of PEG prevents premature destruction by the 
organism’s immune system through the reticuloendothelial system (RES). Liposomes can be 
easily modified in other ways to have ligands or other targeting molecules or peptides on the 
outside of them to aid in correct delivery of their cargo to the desired cells.23,26 
Liposomes as delivery vehicles are not without drawbacks. First, the use of liposomes is 
limited in therapeutics due to their short shelf life once they are prepared.24,28 If they are 
recognized by the immune cells, they can be taken up and inactivated by the RES. This 
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drastically cuts the circulating time of the liposomes and the efficacy of the therapeutic they are 
attempting to deliver. Liposomes have even been shown to induce a complement activation of 
the immune system in rats and pigs.1,23 Besides these specific immune responses, liposomes, 
especially the cationic liposomes, can cause blood clots. Structurally, permeability and integrity 
of the liposome bilayer can change based on the external conditions. Under conditions such as 
high pressure or temperature, liposomes can leak their internal solutes through the bilayer or 
fenestrations can develop within the bilayer, making the bilayer permeable to external solutes 
and solvents.26  
 
Solid Lipid Nanoparticles 
Other nanoparticles, nanocapsules, and nanocarriers have been developed, some of which 
are structurally similar to liposomes. Solid lipid nanoparticles (SLN) are composed of lipids and 
can contain the molecule or therapeutic drug within the small pores inside of them. An advantage 
these have over liposomes is their longer shelf life.24 The sizes of these can also vary, depending 
on how they are made, meaning they can also have a wide range of uses therapeutically. Much 
like liposomes, SLNs can be tuned to release their cargo at defined pH or temperature values.24 
Though the hydrophobicity of them can vary somewhat, SLNs are typically hydrophobic in the 
core as compared to the aqueous-filled core of the liposome. This may mean that many aqueous 
solvents and hydrophilic solutes used therapeutically do not mix well with them, thereby limiting 
their usefulness.24 
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Polymersomes 
Another nanocarrier that has been developed is the polymersome. These have different 
polymers, often times with blocks of repeating subunits within them, as their base units, and have 
been called block copolymers.30 These block copolymers have increased in use and development 
significantly over the past 10 years.  Despite being different with respect to the base units as 
compared to liposomes, these show some structural similarities to liposomes. Encapsulation of 
the solutes and solvents within a hydrophilic core is similar to the structure of liposomes. These 
block copolymers have been shown to be much more stable than liposomes, especially in high 
concentrations above the critical micelle concentration (CMC) and when cross-linkers are used 
to stabilize the structure.32 The content within them can also be released more specifically than is 
seen with liposomes and their size and thickness can be easily modified depending on the 
composition of the polymer.30,31  
These block copolymers are also not without their disadvantages. Though the polymers 
within them are typically non-toxic, they can contain other compounds or components within 
them which can be toxic when delivered in vivo.31 These toxic compounds are typically the 
molecules that are used to increase stability and cross-link the copolymers together. Constructing 
these block copolymers into the functional nanoparticles can also take more time and energy 
with than other nanoparticles and nanocarriers, making them not very cost-effective to use in 
large quantities.25,30,32  
 
Peptide-Based Nanoparticles 
Another type of nanoparticle is that made from organic molecules, such as a peptides or 
proteins that can self-assemble into nanocapsules.33 These nanocapsules are made from mainly 
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the natural amino acids and have many advantages over the traditional liposome delivery 
system.18,21 These peptide nanoparticles have a sequence that has been derived from a peptide or 
protein sequence or developed from de novo design.33 By making these therapeutics out of 
peptides that form nanocapsules, the problematic limited bioavailability, poor biodistribution, 
instability, and short half-lives that are seen with free peptides, especially in the more harsh 
conditions in the body, can be greatly decreased.18,21,34 Also, because they are made from natural 
amino acids, they are non-toxic to the organism upon breakdown.18 Typically, these peptide-
based nanocapsules are assembled non-covalently. This means that they are self-assembled using 
hydrophobic interactions, van der Waals interactions, hydrogen bonding, π-π stacking, and 
electrostatic interactions to make these nanoparticles more tunable to rupture at certain 
conditions.18,35  
Like other nanoparticles, peptide-based nanoparticles also have distinct advantages. 
Many of these peptide-based molecules are typically easy to modify based on the well-known 
chemistry of many of the reactions. For example, these peptide-based systems can be easily 
modified or “tuned” by changing the sequences, by changing the amino acids from L to D 
conformations, or by the addition of carbohydrates, fatty acids, or other molecules onto the 
peptides.17,21,36,37 These modifications can also be made to either intentionally elicit or avoid an 
immune response within the organism, much like was discussed with PEG on liposomes. The 
molecule used would depend on the desired effect-whether it is to deliver a therapeutic where 
minimal immune response is desired or to make a vaccine where more of an immune response is 
required.17,21  
 Other molecules can be easily added to decorate the outside of the nanocapsules to direct 
the capsule where to go in vivo. These areas that can be targeted with peptide-based drugs 
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include the central nervous system, cardiovascular tissue, bones, and tumors, all of which are 
locations that are often difficult to target with other therapeutic systems.17,21,38 This specific 
targeting has been an area of research and therapeutics that has increased sharply over the past 
few years.18 Peptide-based nanoparticles are also very stable, easy to make in large quantities, 
have less extensive assembly preparation, are biodegradable, and are compatible with many 
organisms. 
Peptide nanoparticles can also be used as vectors for gene delivery. Because the DNA or 
RNA is not able to cross the cell membrane on its own, a vector is needed. These delivery 
vehicles may be viral or non-viral, and the peptide carriers fall under the latter.36,39 The viral 
vectors, no matter how modified they have been, still have downfalls such as limited carrying 
capacity, limitations of the types of oligonucleotides they can deliver, incompatibility with 
human genetics, and potentially causing an unintentional immune response.2,36 These limitations 
can be avoided by using peptide delivery vehicles, including peptide nanocapsules. The 
nanocapsules, unlike viral delivery vectors, can easily be prepared in large quantities and have 
the potential for lower toxicity and fewer side effects.2 These peptide delivery systems require 
that the negative charges on the different kinds of DNA or RNA are neutralized or masked, 
which many peptides, especially cationic peptides with lysine and arginine, can do.20,36,40 The 
degradation of the oligonucleotide must also be prevented, and by either covalently attaching 
them to peptides, encapsulating them within peptide nanocapsules, or otherwise affixing them to 
peptide nanocapsules, the oligonucleotides can be transported intact to and into the desired cells 
often using endocytosis.2,36,40 Though there are no nanoparticle gene delivery systems approved 
by the FDA yet, many are working on developing, testing, and advancing these peptide-based 
nanoparticles for use for gene delivery.2  
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Branched Amphiphilic Peptide Capsules 
 
An example of a peptide-based nanocapsule is Branched Amphiphilic Peptide Capsules 
(BAPCs). These branched peptides were first described in Gudlur et al.41 These self-assembling 
nanocapsules are formed from a pair of branched, chemically synthesized peptides which were 
modified from a known calcium channel peptide sequence. These peptides have a similar 
structure to diacyl glycerol molecules; they have amphiphilic character with a polar end 
composed of positively charged lysine residues and a hydrophobic end composed of two tails 
(Figure 1.1). Because of the high percentage of hydrophobic amino acids in each tail, for either 
the 9 or the 5 amino acid residue tails (Figure 
1.1) these peptides were termed h9 and h5 
respectively. Early work done by Gudlur et 
al41 showed that these nanocapsules could 
encapsulate fluorescent dyes and other solutes 
in aqueous solutions but were unstable in 
organic solvents such as trifluoroethanol. 
Coarse-grained modeling supported the idea that they formed nanocapsules.  
Once documented that this peptide pair self-assembled to form peptide-based 
nanocapsules, further biophysical and structural characterization was done to explore how the 
BAPCs behaved under different conditions. Using electron microscopy, the sizes of the nascent 
and mature BAPCs were determined. Once the branched peptides h5 and h9 are combined in 
equimolar amounts and hydrated with water, they immediately begin to form what appears to be 
nano-fibrils. However, by 30 minutes, capsules with a diameter of about 20-30 nm formed. By 2 
Figure 1.1 – Sequences of h9 and h5 peptides 
Shown are the sequences of the self-assembling branched 
peptides h9 and h5. The branch point occurs on the fifth lysine 
residue with branches coming off at amine groups on the N 
terminus and the ε amine of the side chain. 
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hours at room temperature, the sizes of the BAPCs have increased up to 500 nm, suggesting the 
individual BAPCs underwent fusion thereby significantly increasing their size.42  
In order to understand how these BAPCs behaved, fluorescent dyes were used, and one 
dye was found to be paramount in the characterization of the BAPCs: Eosin Y. First described in 
Sukthankar et al42, Eosin Y shows a predictable change in fluorescence based on the 
concentration of the Eosin Y in solution (Figure 1.2). The fluorescence increases with the 
concentration of Eosin Y until the concentration reaches about 150 µM. As the concentration of 
the dye increases further, the fluorescence decreases suggesting that the other molecules of Eosin 
Y begin to self-quench the fluorescence intensity.36 Because of the predictable fluorescence 
changes seen with small concentration changes of Eosin Y, this became an ideal dye for use 
within the BAPCs.  
In Sukthankar et al42, Eosin Y at a concentration of 2.126 mM in water was encapsulated 
Figure 1.2 – Eosin Y fluorescence concentration curve 
The points show the maximum Eosin Y fluorescence intensity at increasing concentrations of Eosin Y in distilled, 
deionized water. (Excitation wavelength: 490 nm; emission range scanned: 495 to 800 nm; quartz cuvette with 0.3 cm 
path length; scan rate: 600 nm/min; PMT detector voltage: 600 V; excitation slit: 2.5 nm; emission slit: 2.5 nm) 
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within BAPCs. These Eosin Y filled BAPCs were mixed with a 20X population of water-filled 
BAPCs, and the fluorescence was monitored. Over time, the fluorescence increased steadily 
indicating that the Eosin Y dye within the 
BAPCs was becoming more diluted over 
time. In order for this to happen, the 
BAPCs had to be fusing thereby mixing 
the contents of the water-filled and Eosin 
Y-filled BAPCs. This data correlates with 
the earlier electron microscopy data that 
showed that BAPCs increased in size due 
to fusion. This work with the BAPCs and 
Eosin Y illustrated the usefulness of Eosin 
Y in the studies of BAPC 
characterization.42  
Further characterization studies 
were published in Sukthankar et al.43 
These studies looked at the circular 
dichroism (CD) spectra to determine the 
secondary structural characteristics of the 
peptides as they move through different 
temperatures (Figure 1.3). It was seen 
that BAPCs composed of h5 and h9 
together and brought to 4°C almost 
Figure 1.3 – CD spectra of BAPCs at 4°C, 25°C, and 37°C 
The CD spectra of the BAPCs with equal molar concentrations of h5 
and h9 peptides. All were made at 25°C and moved to either 4°C or 
37°C after 30 minutes or kept at 25°C. Reprinted with permission 
from reference 43. Copyright 2015 American Chemical Society.  
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immediately adopt a more random coil composition. As the BAPC solutions were warmed to 
37°C, the peptides develop more β-sheet composition. The peptides at room temperature show a 
mix between β-sheet and random coil characteristics in the CD.43  
In Sukthankar et al,43 there was a conformation of BAPCs also identified and 
characterized. These BAPCs are made at room temperature and taken to 4°C before being 
brought back to room temperature. These BAPCs have been shown to resist the TFE-induced 
rupturing that is seen with BAPCs made at the other temperatures, and because of this, these 
BAPCs were named “locked BAPCs”. Using Eosin Y and water BAPCs as previously done, it 
was seen that these locked BAPCs did not fuse as the BAPCs made at room temperature do, even 
when brought to 80°C. This also showed that small temperature changes can change the BAPCs’ 
characteristics and behavior (Figure 1.4).44  
Like many other peptides and nanocapsules previously discussed, BAPCs are also able to 
penetrate the cell membrane. Upon being taken up by HeLa cells in cell culture, they remained in 
HeLa cells for at least two weeks without rupturing. Distinct fluorescent dye-filled capsules can 
be seen in both the parent cells 
and the daughter cells. 
Experiments using temperature 
changes and BAPC uptake 
showed that the entry into the 
cells occurs via the endosomal 
pathway. These BAPCs then 
escape the late endosome, most 
likely due to their positive 
Figure 1.4 – The fates of 25°C BAPCs 
All temperature-induced states are irreversible. It was found that the BAPCs 
hydrated with 4°C or 37°C water form uniform 20-30 nm non-fusogenic capsules 
that rupture in the presence of TFE. Reprinted with permission from reference 43. 
Copyright 2015 American Chemical Society. 
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charges of the many lysine residues and the proton-sponge effect.44,45,46 
BAPCs have also shown biocompatibility, which is a benefit of peptide capsules, and 
preliminary studies have shown a potential use for therapeutics. The first study that showed their 
potential use in therapeutics was seen when 225Ac-loaded BAPCs were injected into mice. As the 
225Ac degrades to 213Bi, daughter alpha particles are released with retention of the daughter 
radionuclides. Alpha-emitting isotopes can cause damage to chromosomes. Liposomes must be 
much larger (too large to be useful) than the BAPCs to overcome the powerful recoil of the 
daughter radionuclides. This rupture does not occur with the BAPCs, though. This shows that 
they are taken up by many different cells within different tissues and can withstand a great deal 
of force and still remain intact. This also shows benefits to these capsules as a delivery vehicle 
and therapeutic aide as compared to the more traditional liposome.44  
Another in vivo study was done in Avila et al47 using the BAPCs as a delivery vehicle for 
DNA vaccines into mice. From previous work, it was known that when locked BAPCs and DNA 
were combined in the appropriate N:P ratios (N being the NH3
+ on the lysine residues and P 
being the PO4
- on the DNA), the DNA and BAPCs would form a complex. These BAPCs 
associated with the DNA would then help the DNA become internalized within the cell and 
transfect the cells with the new genetic material.48 After the mice were injected with these 
BAPCs to deliver the viral DNA from a North American type I porcine and reproductive 
syndrome virus, competent RNA viruses were actually shed. This shows that the genetic material 
can effectively be delivered to an organism without damaging the DNA. Also in this paper, mice 
had DNA:BAPC complexes composed of an HPV E7 containing DNA plasmid. Those mice that 
received the DNA with the BAPCs lived longer and had smaller tumors than those who did not 
have the BAPCs used.47 These recent studies in mice suggest that there is a potential for future in 
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vivo use of these BAPCs, but there had not been much work on how these BAPCs behaved in 
the presence of physiologically pertinent ions like sodium and chloride. 
The interaction with water and ions was first discussed in Jia et al.49 Using molecular 
dynamics simulations, water was shown to flow freely and spontaneously through the bilayer 
without lingering between the peptide leaflets. It can be suggested that the water molecules form 
hydrogen bonds with the peptide backbones of the hydrophobic regions of the peptide. This 
allows the water molecules to move readily and rapidly, even throughout the hydrophobic tail 
regions. When these simulations were done with the presence of sodium or chloride ions, it 
showed that they did not readily cross the bilayer as the water did during the simulation time.  
The selective movement of water but not ions that was seen in the molecular dynamics 
simulations was also seen in experiments with BAPCs with either Eosin Y or Rhodamine 6G 
dyes. These dyes are negatively or positively charged, respectively, and Rhodamine 6G has a 
fluorescence concentration curve nearly identical to the autoquenching curve of Eosin Y shown 
in Figure 1.2. BAPCs were formed with 2.216 mM Eosin Y or Rhodamine 6G dye within them. 
This dye was in a solution of distilled, deionized water or NaCl (concentrations of 20, 50, 100 or 
300 mM). The BAPCs containing dye and distilled, deionized water were divided in half. One 
half was suspended in water and the other half was suspended in 1 M NaCl. The fluorescence of 
these solutions were taken immediately after suspension in the water or NaCl. The BAPCs 
containing dye and NaCl were treated similarly. They were suspended in the isotonic solution of 
NaCl in which they were made and also suspended in distilled, deionized water. Fluorescence 
readings were taken immediately after suspension of these BAPCs as well. The fluorescence 
values of the BAPCs in the isotonic solutions were subtracted from the fluorescence values of 
the BAPCs in the hyper- or hypotonic solutions. The resulting values can be seen in Figure 1.5. 
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The bars that extend below 
the zero point in the graph 
show fluorescence values 
that are smaller after they 
are moved to the NaCl 
solution. This decrease in 
fluorescence suggests that 
the Eosin Y and 
Rhodamine 6G dyes within 
the BAPCs are becoming 
more concentrated, which 
suggests that the water is 
flowing out of the BAPC 
due to osmotic changes in the solution surrounding them. The bars that extend above the zero 
line in the graph show fluorescence values that are greater once the BAPCs containing NaCl-dye 
solution are moved into water. This data seems to show that water is also moving into the 
BAPCs in a NaCl concentration dependent manner. After the external solutions were changed, 
the BAPCs were then filtered again and the flow-through was checked for fluorescence. This 
flow-through did not have any detectible fluorescence, suggesting that all of the fluorescence 
changes were from inside of the BAPC, not from dye released into the solution outside of the 
BAPC, and the BAPCs remained intact and stable through the changes of saline concentration.49  
Figure 1.5 – Fluorescence intensity differences of DW- and NaCl-filled BAPCs 
Shown are the fluorescence values of the BAPCs in hypo- or hypertonic solutions minus 
the fluorescence of the same BAPCs in the isotonic solutions. Shown are Eosin Y and 
Rhodamine 6G-containing BAPCs made to encapsulate increasing concentrations of 
NaCl along with the dye. The NaCl concentrations are shown on the horizontal axis and 
the difference in percent is shown on the vertical axis. It is suggested that the change seen 
between Rhodamine 6G and Eosin at high salt concentrations may be due to the large 
fluorescence changes seen with Rhodamine 6G in NaCl. Error bars represent standard 
error of the mean with n≥3. Reprinted with permission from reference 49. Copyright 2016 
American Chemical Society. 
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When these relative changes in Eosin Y fluorescence are plotted on a fluorescence curve 
of Eosin Y, the approximate final concentrations, and therefore the approximate sizes, can also 
be estimated (Figure 1.6). By assuming that the beginning BAPC that contains 2126 µM Eosin 
Y is 20 nm in diameter, the following could be calculated: 5000 µM Eosin Y is 15 nm diameter, 
1375 µM Eosin Y is 23 nm in diameter, 1250 µM Eosin Y is 23.9 nm in diameter, 800 µM Eosin 
Y is 27.7 nm in diameter, and 500 µM Eosin Y is 32.4 nm in diameter. All of these numbers are 
within the known limits of the sizes of these capsules, which shows that it these numbers are not 
Figure 1.6 – Approximate normalized internal dye concentration 
The line shows the average Eosin Y fluorescence at increasing concentrations. The scanning parameters were the same as 
used in Figure 1.2. To find the normalized fluorescence, each fluorescence intensity was calculated as a percent of the 
maximum. The value at 2126 μM was subtracted from each. The marked points on the graph show approximate locations 
where percent fluorescence values from the NaCl or water BAPCs seen in Figure 1.5 fall on this line. (Red X = 300 mM 
NaCl BAPCs; Orange Circle = 100 mM NaCl BAPCs; Green Triangle = 50 mM NaCl BAPCs; Blue Diamond = 20 mM 
NaCl BAPCs; Purple Square = Water BAPCs). Error bars represent SEM and n≥3. Reprinted with permission from 
reference 49. Copyright 2016 American Chemical Society.  
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outside of the realm of possibility. This data suggests that the BAPC bilayer can act as a semi-
permeable membrane allowing ions and solvents to remain on one side while water passes freely 
through instantaneously.49  
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Chapter 2 – Water-filled BAPCs in Varying External Solutions 
Materials and Methods 
Peptide synthesis 
 The h5 and h9 peptides were synthesized on an ABI 431 automated peptide synthesizer 
using Fmoc chemistry on 0.1 mmol scale using CLEAR amide resin (Peptides International, 
Louisville, KY). All amino acids were N-Fmoc protected amino acids (P3 Biosystems, 
Louisville, KY and AnaSpec, Fremont, CA) and used at 0.5 mmol per synthesis. The N-terminal 
lysines were double coupled, and the branch point was introduced into the sequence by using a 
lysine with an Fmoc protecting group on both the α- and the ε-amino groups as compared to the 
Boc protecting groups on the ε-amino groups on the other lysines. The amino acids of the 
hydrophobic tails were all triple coupled. Piperidine (99% Purity, Sigma-Aldrich, St. Louis, MO) 
was used in NMP to remove the Fmoc and deprotect the amino-terminal groups. Activation of 
each amino acid was done using a solution of 0.225 M HOAt/HATU in DMF. After the final 
amino acid was added and the Fmoc removed, the amino terminus was protected using acetyl 
anhydride. For h9 only, the initial lysine was added off of the peptide synthesizer, activated, and 
only allowed to react for five minutes. Once the five minute was completed, the resin was rinsed 
with NMP and capped with the acetyl capping cocktail to block any other unoccupied active sites 
on the resin. The remainder of the synthesis was completed as described above on the automated 
peptide synthesizer. This method is used to eliminate sterically inaccessible sites on the resin that 
could eventually result in numerous failed sequences by the time the last amino acid was added. 
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Peptide Cleavage and Deprotection 
 The peptides were cleaved from the resin using a solution of 98% TFA and 2% distilled, 
deionized water. This was mixed at room temperature for 90 minutes in order to cleave peptide 
from resin and remove protecting groups from amino acid side chains. The slurry was put 
through a filter and the liquid poured into ice cold diethyl ether to precipitate peptide. The 
peptide was then washed with diethyl ether three times. The h5 peptide was then suspended in 
distilled deionized water and lyophilized. The h9 peptide was dried directly from the diethyl 
either without suspending in water. Adding h9 to water results in its adopting β-structure leading 
to the formation of insoluble aggregates. Once dried, the peptide was analyzed using reverse 
phase HPLC on a Beckman machine running 32 Karat (version 8.0) software with a C18 column 
(Buffer A: 99.9% water and 0.1% TFA; Solvent B: 90% Acetonitrile, 9.9% water, and 0.1% 
TFA) with a 10% to 90% Buffer B gradient over 30 minutes. MALDI-TOF MS was also used for 
analysis with the peptide spotted in a DHB matrix (Sigma-Aldrich, St. Louis, MO) on a Bruker 
Ultraflex II machine.  
 
Preparation of Peptide Solutions 
 Once peptides were dried, a small amount of each was dissolved in 100% TFE and 
absorbances were taken at 257.5 nm in a 0.3 cm path length quartz cuvette (Cary UV/Vis 
Spectrometer, Varian Inc., Palo Alto, CA). Using Beer’s Law where A=εcl (A=absorbance, 
ε=molar extinction coefficient (195 M-1cm-1 for Phe at 257.5 nm), c=concentration of the 
solution, l=pathlength of the cuvette), the precise concentration of the peptides the TFE solution 
could be determined from the absorbance values of the phenylalanine of the peptides in solution. 
From this, 300 µL of 1 mM concentration of both h5 and h9 were combined and dried in a new 
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tube in the Speedvac, unless another concentration and volume were specified. These were made 
within one or two days of use as this showed the most consistent results. 
 
Fluorescence Assay of 5(6) Carboxyfluorecein in Variable pH 
The peptides were combined and prepared as described above but instead equimolar 
concentrations of 5 mM each peptide were used. Once dried, they were hydrated in a drop-wise 
fashion with 200 µL of 4°C 1.5 mM 5(6)Carboxyfluorescein (Sigma-Aldrich, St. Louis, MO) 
dissolved in water. These were moved to 4°C for another 30-45 minutes. . 
After this incubation time, the BAPC plus peptide solutions were transferred to an 
Amicon Ultra-0.5 mL centrifugal cellulose filter with 30 kDa molecular weight cut-off (EMD 
Millipore, Billerica, MA) and centrifuged at 14000 x g for 5 minutes in an Eppendorf 5415 D 
benchtop centrifuge. External dye passed through the filter while the 5(6)Carboxyfluorescein-
containing BAPCs remained in the filter. 
 The BAPC solution retained in the filter was washed twice with a 300 mM solution of 
Na-TFA (Sigma-Aldrich, St Louis, MO) in distilled, deionized water solution to remove any 
externally-bound dye molecules. The BAPCs were then washed with water to remove any 
additional external dye from the solution around the BAPCs. The filters were then inverted into 
clean tubes and centrifuged at 2000 x g for 5 minutes to remove the BAPCs from the filters. The 
recovered retentate was then divided into two equal amounts into clean tubes for fluorescence 
analysis.  
The two samples were then suspended in either pH 2 HCl and distilled, deionized water 
or 100 mM pH 9 Tris Buffer and distilled, deionized water. Fluorescence was obtained on a 
CARY Eclipse fluorescence spectrometer (Varian Inc., Palo Alto, CA, scan rate: 600 nm/min; 
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PMT detector voltage: 600 V; excitation slit: 5 nm; emission slit: 5 nm). An excitation 
wavelength of 492 nm was used and the fluorescence was obtained from 500 to 700 nm within a 
0.3 cm path length quartz cuvette. Solutions of 37.5 µM 5(6)Carboxyfluorescein were also made 
within the solutions of pH 2 HCl, distilled, deionized water, or 50 mM pH 9 Tris Buffer. These 
were scanned as above with the exception of the excitation and emission slits of the CARY 
Eclipse being 2.5 nm for the dye solutions. 
 
BAPC Formation with Eosin Y 
 Once dried from TFE solution, the 1 mM/300 µL h5h9 peptides were hydrated in a drop-
wise fashion with 300 µL of a room temperature solution of 2.126 mM Eosin Y (Sigma-Aldrich, 
St. Louis, MO) dissolved in water. To make room temperature BAPCs, the tubes were allowed to 
sit at room temperature for 30-45 minutes without mixing and filtered as described below. 
 To make locked BAPCs, the BAPCs were hydrated with 300 µL of a room temperature 
solution of 2.126 mM Eosin Y solution. After 30-45 minutes, the tubes were moved to 4°C for at 
least 30-45 minutes. The BAPC solution was then removed from 4°C and brought back to room 
temperature by sitting on the benchtop for an additional 30-45 minutes.  
 Once the incubation time was completed, the dye plus peptide solutions were passed 
through a pre-wet 0.22 µm PTFE syringe-driven filter (EMD Millipore, Billerica, MA) to 
remove the larger dye-peptide aggregates. This was put directly into an Amicon Ultra-0.5 mL 
centrifugal cellulose filter with 30 kDa molecular weight cut-off (EMD Millipore, Billerica, MA) 
and centrifuged at 14000 x g for 5 minutes in an Eppendorf 5415 D benchtop centrifuge. BAPCs 
in solution were retained in the filter while any external dye was passed through the filter. 
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 The retained BAPC solution was washed twice with a 300 mM solution of Na-TFA 
(Sigma-Aldrich, St Louis, MO) in distilled, deionized water solution in order to remove any 
externally-bound dye molecules. The BAPCs were then washed with water at least four 
additional times to remove the salt solution and any additional dye molecules from the solution 
around the BAPCs. The filters were then inverted into clean tubes and centrifuged at 2000 x g for 
5 minutes to remove the BAPCs from the filters. The recovered retentate was then divided into 
two equal amounts into clean tubes for fluorescence analysis.  
 
Fluorescence Assays of Eosin Y BAPCs in NaCl 
 One half of the BAPC solution filtered through the Amicon Ultra-0.5 mL centrifugal 
cellulose filters with 30 kDa molecular weight cut-off filter was suspended in 300 µL distilled, 
deionized water and the fluorescence was scanned on a CARY Eclipse fluorescence spectrometer 
(Varian Inc., Palo Alto, CA, scan rate: 600 nm/min; PMT detector voltage: 600 V; excitation slit: 
10 nm; emission slit: 10 nm). An excitation wavelength of 500 nm was used and the fluorescence 
from 505 to 700 nm within a 0.3 cm path length quartz cuvette was obtained. The other half of 
the solutions were resuspended in NaCl solutions of either 10, 20, 50, 100, or 300 mM NaCl and 
fluorescence measurements taken as described above immediately after addition of NaCl 
solution and every 2 minutes over 90 minutes. Once these scans were completed, the BAPC 
solution from the cuvette was transferred back into an Amicon Ultra-0.5 mL centrifugal cellulose 
filter with 30 kDa molecular weight cut-off filter and centrifuged at 14000g for 5 minutes. The 
filter was then inverted into a clean tube and spun again at 2000g for an additional 5 minutes to 
remove the BAPC solution from the filter. This BAPC solution was then resuspended in 300 µL 
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water and fluorescence measurements taken immediately after the addition of water and every 2 
minutes over 30 minutes.  
The values at 538 nm were taken from each run and the values were adjusted to account 
for the blank – the change in fluorescence of BAPCs suspended in pure water and treated in the 
same manner. Each NaCl concentration was repeated at least three times. Percent change from 
water was then calculated and the starting time zero value was normalized to 100% for the 
BAPCs in the salt solutions. For the BAPCs that were put back into water, the final scan was 
taken to equal 100% and the other values of the scans were taken as a percentage of that.  
 
Circular Dichroism 
 For circular dichroism (CD) studies on the BAPCs, peptide concentrations were 
measured as previously discussed and 2 mM/150 µL of both h5 and h9 were used for these 
studies. These peptide solutions were hydrated with 150 µL distilled, deionized water at room 
temperature and allowed to sit for 30-45 minutes. For the locked BAPCs, the BAPCs were 
hydrated with the 150 µL of room temperature distilled, deionized water and allowed to sit at 
room temperature for 30-45 minutes. Then, the tubes were moved to 4°C for at least 30-45 
minutes. The BAPC solution was then brought back to room temperature by allowing the tubes 
to sit on the benchtop for an additional 30-45 minutes. 
After the incubation time was completed, the solution was divided equally into two tubes. 
To one of the tubes was added 75 µL distilled, deionized water, and the absorbance of this was 
taken at 257.5 nm as discussed in the section Preparation of Peptide Solutions. The CD spectra 
of the BAPC solution in water were obtained from 260-190 nm at 50 nm min−1 with 1 nm step 
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intervals using a Jasco J-815 CD spectrophotometer (Jasco Analytical Instruments, Easton, MD) 
in a 0.2 mm path-length cylindrical quartz cuvette (Starna Cells Inc., Atascadero, CA).   
Once the scan in water was completed, to the other half of the solution, 75 µL of NaCl of 
the appropriate concentrations was added to bring the total concentration in the tubes to 10, 20, 
50, 100, or 300 mM NaCl and pipetted to mix. Immediately after addition of NaCl, the BAPC 
solution CD spectrum was obtained. Once this scan was completed, the sample was left in the 
cuvette and scanned again after 90 minutes.  
After the 90-minute scan was completed, the BAPC in NaCl solution was transferred to a 
Amicon Ultra-0.5 mL centrifugal cellulose filters with 30 kDa molecular weight cut-off (EMD 
Millipore, Billerica, MA) and centrifuged at 14000 x g for 5 minutes. This solution was washed 
with distilled, deionized water once and centrifuged again. The filter was then inverted into a 
clean tube and centrifuged at 2000 x g for 5 minutes to recover the BAPCs. The BAPC solution 
was resuspended in 150 µL water and the absorbance of this solution was also taken at 257.5 nm 
as described above in order to determine the concentration. This was then put back into the CD 
cuvette and the spectrum was again scanned as above from 260-190 nm initially after adding the 
distilled, deionized water to the BAPCs and after 30 minutes.  
The CD data was obtained in mdeg values, an average of 5 scans was used, and a blank 
of either water or the appropriate NaCl solution concentration was subtracted from the raw 
sample spectra. The spectra were smoothed using a Savitsky−Golay filter within the Spectra 
Analysis software (Jasco Inc., Easton, MD). Mean residue ellipticity was calculated using this 
equation: 
  Mean Residue Ellipticity = Θ (n × c × l)⁄  
Θ = CD measurement value in mdeg 
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n = number of peptide bonds in h5 and h9 
C = Concentration (M) 
l = cuvette path length in cm  
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Permeability of pH Variations in 5(6)Carboxyfluorescein-containing BAPCs 
 Initial studies of the permeability of the BAPC bilayer began with an examination of the 
permeability of the bilayer to hydronium and hydroxide ions. In order to do this, we took 
advantage of the pH-induced fluorescence changes of 5(6)Carboxyfluorecein dye. This dye alone 
in solution showed significant changes as the pH was examined from very acidic to basic 
(Figure 2.1 Panel A). As the pH increased from 2 to 9, the fluorescence of the dye solution also 
increased about 60 absorbance 
units between each pH change.  
 When the BAPCs were 
prepared with encapsulated 
5(6)Carboxyfluorescein, the same 
trend that was seen with the dye in 
solution was seen with the 
encapsulated dye (Figure 2.1 
Panel B). This shows that 
hydronium and hydroxide ions 
move rapidly and readily through 
the BAPC bilayer. This early data 
shows that we have a membrane 
that can allow water to pass freely 
through and may even allow other 
small molecules.  
A 
B 
Figure 2.1 – Effects of pH on 5(6)Carboxyfluorescein in Solution and 
BAPCs 
Panel A – 37.5 µM 5(6)Carboxyfluorescein dissolved in solution listed.  
Panel B – BAPCs containing 1.5 mM 5(6)Carboxyfluorescein in water then 
moved to solution listed. Dashed line shows data in Tris Buffer pH 9, dash-dot 
line shows data in pure water, and solid line shows data in pH 2 HCl. Graphs 
show representative data of all runs with n≥3. 
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Results of Room Temperature BAPCs in NaCl 
Eosin Y Room Temperature BAPC Fluorescence Studies 
 The purpose of the fluorescence measurements of the Eosin Y-filled BAPCs was to 
determine the fluorescence change of Eosin Y, which can be then correlated to dilution and size 
changes within the BAPC populations. Previous work showed that there did not appear to be any 
ion flow, only water molecules, through the peptide bilayer.49 When the water-filled BAPCs’ 
fluorescence were monitored over time in saline solutions, there was an apparent trend that is 
related to the NaCl concentration (Figure 2.2).  It can be seen that the fluorescence of the 
BAPCs in the 10 mM and 20 mM NaCl solutions does not vary much from the initial 
fluorescence intensity. This suggests that there is very little Eosin Y concentration change and 
BAPC size fluctuation within these lower concentration saline solutions.  
As the NaCl concentrations increases to 50, 100, and 300 mM, it can be seen that there is 
a marked decrease in the fluorescence intensity with the most intense decrease in fluorescence 
seen within the first 20 minutes after the BAPCs are placed in the saline solution. This suggests 
that the Eosin Y within the BAPCs is becoming more concentrated; this is occurring rapidly 
initially and then the fluorescence remains at about the same level for the remainder of the scans. 
The decrease in fluorescence intensity occurs in a NaCl concentration-dependent manner, though 
the 100 mM and 300 mM NaCl curves look similar in both curve and end value. Looking at 
these curves, it suggests that there is a minimum concentration of NaCl needed in order to drive 
noticeable water flow out of the BAPCs. It also suggests that the BAPCs can only compress to a 
certain size, and even with increasing external salt concentration and osmotic pressure, these 
BAPCs are not able to become any smaller in diameter.  
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By looking at only the fluorescence values of the 90-minute time points (Figure 2.3), the 
data that the BAPCs only seem to be able to compress to a certain size can be seen more clearly. 
This data shows that the fluorescence changes that occur from 10 to 50 mM NaCl occur in an 
almost linear fashion, but at a concentration around 100 mM NaCl, the BAPCs have compressed 
Figure 2.2 – Room temperature BAPCs in 
NaCl solutions 
Shown are the changes in the percent 
fluorescence intensities. Panel A shows the 
curves including the data from BAPCs in water 
alone. Panel B shows the corrected 
fluorescence curves when the water values are 
taken into consideration. Horizontal axis shows 
the time in minutes from the addition of the 
saline solution, and the vertical axis has the 
fluorescence percent values. Error bars show 
SEM with n≥3. 
A 
B 
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as much as they are able to 
compress, and increasing the 
saline solution concentration 
even up to 300 mM does little 
to further change the BAPC 
size after 90 minutes.  
Once these room 
temperature BAPCs have had 
water removed from the 
internal space and become 
more compact, the question then is whether these BAPCs can re-expand when suspended back in 
a water solution. Figure 2.4 shows the data of these BAPCs once re-suspended in water after the 
90 minutes in a saline solution. When comparing the fluorescence values to those of the final 
fluorescence, it is seen that there is an increase in fluorescence intensity through all of the 
concentrations of NaCl. Unlike the graphs seen in Figure 1.6 that showed a concentration-
dependent change in fluorescence, these do not follow the concentration of NaCl from which 
they were taken. It can be seen here that the BAPCs re-suspended from the 20 mM NaCl solution 
show the greatest percent increase in fluorescence, which is interesting since they showed little 
change in fluorescence when put into the NaCl solution. The other BAPCs from the other 
concentrations of saline solutions also show increasing fluorescence, suggesting that water is 
moving back into the BAPCs, diluting the Eosin Y within the BAPCs, and therefore, increasing 
the fluorescence intensity of the Eosin Y.  
Figure 2.3 – Room temperature BAPC fluorescence values at 90 minutes 
Shown are the 90 minute values from Figure 2.2A plotted in relation to the 
concentration of NaCl on the horizontal axis. Error bars show SEM with n≥3. 
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The fluorescence intensity of the initial BAPC scan in water as compared to the final 
BAPC scan after re-suspension in water can be evaluated to suggest whether the re-suspension of 
BAPCs allowed the BAPCs to return to their original size. The initial fluorescence divided by the 
final fluorescence and multiplied by 100 gives us the percent values seen in Figure 2.5. The 
Figure 2.4 – Room temperature BAPCs back 
to water after NaCl 
Shown are the changes in the percent 
fluorescence intensities in relation to the final 
fluorescence intensity. Panel A shows the curves 
including the data from BAPCs in water alone. 
Panel B shows the corrected fluorescence curves 
when the water values are taken into 
consideration. Horizontal axis shows the time in 
minutes from the resuspension of the filtered 
BAPCs back into water, and the vertical axis has 
the fluorescence percent values. Error bars show 
SEM and n≥3.  
 
A 
B 
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graph shows that both 10 mM and 20 
mM NaCl BAPCs have values less 
than 100%. A number less than 
100% suggests that the initial 
BAPCs are larger (have more dilute 
Eosin Y and higher fluorescence) 
than the final BAPCs that were 
moved back into water after being in 
the salt solutions. From this, it seems 
as though the BAPCs suspended in 
these two saline concentrations are unable to return to their original size, even after re-
suspension in water and removal of the NaCl. The other saline concentrations show averages that 
are greater than 100%. Those values larger than 100% suggest that the final size of these BAPCs 
is larger (have more diluted Eosin Y and a higher fluorescence intensity) than the initial size 
based on Eosin Y fluorescence. Though those BAPCs that were in 10 and 20 mM NaCl did not 
seem to show re-expansion to the same size, this highly suggests that the BAPCs are capable of 
an elastic contraction and expansion to some extent due to osmotic pressure. This expansion and 
contraction occurs with minimal breakage of the BAPCs, and this can be nearly reversible in 
regards to the sizes of the BAPCs in the solution. 
  
Figure 2.5 – Room temperature BAPCs initial versus final fluorescence 
Shown is the percent of the final fluorescence after resuspension in water as 
compared to the initial fluorescence in water. Values less than 100 suggest 
that the final BAPC size is smaller than the original size, and values greater 
than 100 suggest that the final BAPC size is larger than the initial. Error bars 
are SEM and n≥3. 
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Room Temperature BAPC Circular Dichroism Studies 
 The fluorescence studies done on BAPCs in saline solutions showed that the BAPCs have 
elastic qualities but cannot show how the molecular structure changes due to the saline solution 
and compression of the BAPC. Previous CD analysis has shown that BAPCs adopt a β-sheet 
secondary structure upon the addition of NaCl into the solution (data not shown). The earlier 
work, however, did not show how this secondary structure tendency changed over time, if at all, 
and whether this secondary structure was reversible when the NaCl was removed from the 
solution. Figure 2.6 shows the CD spectra of the BAPCs. All of the initial BAPCs in water show 
more random coil structure within the secondary structure of the β-sheet as seen by the lessened 
intensity (more negative) of the values at 195 nm as compared to a pure β-sheet spectrum, which 
would have a large positive number. Throughout all of the concentrations of NaCl, the CD 
spectra of the BAPCs shifts to a more pure beta-sheet secondary structure once the NaCl is added 
to the BAPCs. This can be seen by the strong tendency of the mean residue ellipticity seen at 195 
nm to shift to a larger, positive number and the mean residue ellipticity seen at 218 nm to shift to 
a larger, negative number. It can be seen that there is not much change in the secondary 
structural characteristics as the BAPCs are allowed to sit in the saline solutions, regardless of the 
concentration of these solutions. This shows that the effect of the saline solution on secondary 
structure within the peptides of these room temperature BAPCs happens immediately with little 
change seen after the initial change occurs. 
Once the BAPCs were removed from the saline solutions and re-suspended in water, it 
can be clearly seen that the CD spectra of the BAPCs does not return to the original spectra, 
though there are some changes seen in the spectra of the BAPC with and after the addition of 
NaCl. This suggests that the BAPCs’ secondary structures are not just temporarily changed by 
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the addition of NaCl. The CD spectra seen from BAPCs in 10 mM NaCl suggests that the 
BAPCs lose some of their β-sheet characteristics once the NaCl is removed and replaced with 
A B 
C D 
E 
Figure 2.6 – Room temperature BAPC CD spectra 
Panels A-E show the CD spectra of BAPCs in NaCl solutions with concentrations as follows: A – 10 mM NaCl, B – 20 mM 
NaCl, C – 50 mM NaCl, D – 100 mM NaCl, E – 300 mM NaCl. The vertical axis shows mean residue ellipticity and the 
horizontal axis is the wavelength. 
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pure water. None of the other spectra show this same trend, and BAPCs suspended in 20 mM 
and 300 mM NaCl even show more β-sheet characteristics in the CD spectra once the NaCl is 
replaced with water. This data shows that once NaCl has been in the solution, especially in 
concentrations greater than or equal to 20 mM, the BAPC’s secondary structure change is 
essentially permanent. These structural changes cannot be reversed by removing almost all of the 
NaCl from the BAPCs, suggesting that the salt drives some kind of reorganization effect within 
the peptides of the BAPCs.  
  
 
  
34 
Results of Locked BAPCs in NaCl  
Eosin Y Locked BAPC Fluorescence Studies 
 As discussed previously, the locked conformation BAPCs are BAPCs that have been 
made at room temperature and moved to 4°C and back to room temperature. These BAPCs have 
Figure 2.7 - Locked BAPCs in NaCl Solutions 
These plots show the changes in the percent 
fluorescence intensities. Panel A shows the 
curves including the data from BAPCs in water 
alone. Panel B shows the corrected fluorescence 
curves when the water values are taken into 
consideration. Horizontal axis shows the time in 
minutes after the addition of the saline solution, 
and the vertical axis has the fluorescence percent 
values as compared to the initial fluorescence 
value. Error bars show SEM with n≥3. 
 
A 
B 
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unique properties and show promising results for nucleic acid delivery and other potential 
applications. Due to the potential that these BAPCs have experimentally and therapeutically, it is 
more important to understand how different conditions, especially those conditions that a BAPC 
would encounter in vivo, change the sizes and affect the BAPCs overall. Using Eosin Y as a 
gauge for the internal concentration, once again, water flow into and out of the BAPCs can be 
monitored by measuring changes in the fluorescence intensity.  
 When locked conformation BAPCs were put into increasing salt concentrations, there 
was little change seen in the 
fluorescence values over the 90 
minutes during which the scans 
were done (Figure 2.7). In a 
concentration-dependent 
manner, the BAPCs within the 
10 mM NaCl solution do not 
have much change in 
fluorescence values, and the 20 
and 50 mM NaCl solutions show 
a slight decrease in fluorescence over the course of the 90 minute scans. This decrease in 
fluorescence suggests that the Eosin concentration within the BAPCs is increasing as water is 
moving out. The fluorescence values for the BAPCs within the 100 and 300 mM NaCl solutions 
do not continue to decrease as expected, though. They follow a curve that is nearly identical to 
the curve seen for the BAPCs in the 20 mM NaCl. This seems to suggest that there is no more 
water flow out of the BAPCs suspended in 100 or 300 mM NaCl than there is from those BAPCs 
Figure 2.8 – Locked BAPC fluorescence values at 90 minutes 
Shown is the data from the final time point in Figure 2.7A plotted in relation to 
NaCl concentration on the horizontal axis. Error bars show SEM with n≥3. 
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in 20 mM NaCl despite being in about a 10 fold higher salt concentration. The majority of this 
fluorescence change occurs in the first 20 minutes, much like we saw in the room temperature 
BAPCs.  
These total percent fluorescence changes can more clearly be seen by visualizing only the 
Figure 2.9 – Locked BAPCs back to water 
after NaCl  
These plots show the changes in the percent 
fluorescence intensities in relation to the final 
fluorescence intensity once the BAPCs are 
returned to water. Panel A shows the curves 
including the data from BAPCs in water alone. 
Panel B shows the corrected fluorescence 
curves when the water values are taken into 
consideration. Horizontal axis shows the time 
in minutes from the resuspension of the BAPCs 
back into water, and the vertical axis has the 
fluorescence percent values. Error bars show 
SEM and n≥3.  
 
A 
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final percent values after the 
90 minutes of scanning were 
completed (Figure 2.8). The 
BAPCs within the 10 mM 
NaCl solution remain close 
to their original fluorescence 
throughout the 90 minutes, 
and final fluorescence of the 
BAPCs within 20 and 50 
mM NaCl decreases in an almost linear fashion in a concentration-dependent manner with the 
BAPCs in 50 mM NaCl being at about 85% their original fluorescence. The NaCl concentration-
dependent trend does not continue for the 100 and 300 mM NaCl solutions. Instead, they show a 
final fluorescence value that is about 95% of the original value, which is quite similar to that 
seen for those in 20 mM NaCl solution BAPCs.  
 When these same locked BAPCs were transferred back into pure distilled, deionized 
water, the fluorescence effects were quite interesting. Unlike previously seen with the room 
temperature BAPCS, these locked BAPCs have a continued decrease in fluorescence even after 
transfer back to water. It can be seen that it is up to a 40% change in fluorescence as compared to 
the final fluorescence (Figure 2.9). Based on the known trends of Eosin Y fluorescence, this 
suggests that the BAPCs are continuing to move water out of the internal compartment of the 
BAPC and shrink in size, further concentrating the Eosin Y located inside of the BAPC. This 
adds to the data showing that these locked BAPCs have unique properties that are not well 
understood at all times.  
Figure 2.10 – Locked BAPCs initial versus final fluorescence 
Data shows the percent of the final fluorescence of BAPCs resuspended in water as 
compared to the initial fluorescence in water. Values less than 100 suggest that the 
final BAPC size is smaller than the original size, and values greater than 100 suggest 
that the final BAPC size is larger than the initial. Error bars are SEM and n≥3. 
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 This previous data in Figure 2.9 is somewhat contradicted by taking the initial versus the 
final fluorescence of the BAPCs in water. It is clearly seen in Figure 2.10 that the values of 10, 
50, and 100 mM NaCl lie at or above 100%, suggesting that the final size of the BAPCs exceeds 
the initial size. Though this is not fully supported by the data reported in Figure 2.9, it also 
suggests that the locked BAPCs, much like the room temperature BAPCs previously discussed, 
are flexible and have a dynamic bilayer system that allows for expansion and contraction. Unlike 
the room temperature BAPCs, locked BAPCs seem to have a greater tendency to remain at or 
return to at least their initial size even after being in a saline solution. 
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Locked BAPC Circular Dichroism Studies 
Previously published work, as discussed earlier, has shown a difference in the secondary 
structure of BAPCs that have been taken to 4°C. Even when these BAPCs are then brought back 
to 25°C (like the locked BAPCs), they still retain some of the random coil structural 
characteristics of those BAPCs seen at 4°C. This can be clearly seen in the circular dichroism 
data in Figure 2.11. The initial curves of the BAPCs in water show a more negative number at 
195 nm as compared to those initial curves of the room temperature BAPCs (Figure 2.6). This 
negative number at this wavelength corresponds to random coil secondary structure. There is still 
a large negative number at 218 nm which is associated with the β-sheet secondary structure.  
 Even with the random coil characteristics seen in the locked BAPCs prior to the addition 
of NaCl, BAPCs in a solution of NaCl in all of the concentrations tested show a strong β-sheet 
signal with mean residue ellipticity being a large, negative number at 218 nm coupled with a 
large, positive number at 195 nm. The presence of these β-sheet characteristics seems to increase 
with the concentration of NaCl, but even the 10 mM NaCl spectra show a definite and noticeable 
shift toward β-sheet secondary structure. As the BAPCs sit in these saline solutions, there is also 
minimal change in the structural spectra. This shows that most of the changes that occur in the 
secondary structure occur upon immediate contact with the ions. Prolonged contact with a 
solution containing NaCl does not seem to change the structural arrangement much. 
 This β-sheet structure remains even after the salt is removed in all of the samples tested, 
and none of these BAPCs return to their original secondary structural spectrum. In the BAPCs 
within the 10, 20, and 100 mM NaCl, the β-sheet spectral characteristics actually became more 
pronounced when the NaCl was removed. Even those these locked BAPCs seem to have less 
elasticity or change as seen in the Eosin Y studies, their structure seems to change readily and 
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rapidly in the presence of NaCl in the surrounding solution. These locked BAPCs also resist 
many other changes as previously discussed from earlier publications, but they are not resistant 
to the semi-permanent or permanent changes from the addition of external NaCl. 
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A B 
C D 
E 
Figure 2.11 – Locked BAPC CD spectra 
Shown in panels A-E are the CD spectra of BAPCs in NaCl solutions in the panels as follows: A – 10 mM NaCl, B – 20 mM 
NaCl, C – 50 mM NaCl, D – 100 mM NaCl, E – 300 mM NaCl. The vertical axis shows mean residue ellipticity and the 
horizontal axis is the wavelength. 
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Chapter 3 – Discussion and Future Work 
Discussion 
By looking at the changes that occur with the apparent sizes of the room temperature 
versus locked BAPCs, it looks as though the locked BAPCs do not have the same ability to 
shrink and swell as the room temperature BAPCs. The room temperature BAPCs seem to 
decrease in size in relation to the concentration of the saline solution, but the locked BAPCs do 
not decrease to the same extent 
when moved to higher salt 
concentrations (Figure 3.1). 
Previous work has shown that 
the locked BAPCs are 
structurally and 
characteristically distinct from 
the room temperature BAPCs. 
This data presented here agrees 
with that. The rearrangement of 
the peptides within the BAPC 
during the temperature shifts that produce the locked BAPC also modifies the elasticity of the 
peptide bilayer.  
When the BAPCs are returned to water after being in saline solutions, the room 
temperature BAPCs show a predictable increase in the fluorescence, suggesting that water is 
moving back into the BAPCs as expected (Figure 2.4, Figure 2.9). Oddly, this same trend is not 
seen in the locked BAPCs. Though the locked BAPCs show a change when moved back into a 
Figure 3.1 - Room Temperature and Locked BAPCs Final Fluorescence 
Shown is the combined data from Figure 2.3 and Figure 2.8. The data from the 
locked BAPCs is shown in a solid line and the data from the room temperature 
BAPCs is shown in a dashed line. Error bars show SEM with n≥3. 
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water solution, it is not the fluorescence direction expected (Figure 2.9). Comparing the actual 
beginning and ending fluorescence values in water in both locked and room temperature BAPCs 
do show commonalities. Room temperature and locked BAPCs both showed that they were able 
to reach the same, if not higher, fluorescence values after being moved back into water (Figure 
2.5, Figure 2.10). This raw fluorescence data shows that the BAPCs have the ability to re-
expand to greater than their original size, depending on the saline concentration. This suggests 
that the temperature-induced changes that occur to make these locked BAPCs unique from the 
room temperature BAPCs also modifies their compressibility from the osmotic pressure of the 
saline solutions and makes them have less of a tendency to decrease in size than those BAPCs 
formed at room temperature, even when in concentrated saline solutions. This work done with 
Eosin Y BAPC fluorescence seems to agree with previously published data and molecular 
modeling.  
It does not seem as though a charged ion, such as sodium or chloride in solution, can 
readily cross the BAPC bilayer, much like is seen with the phospholipids of the cell membrane. 
These unique properties of strength, flexibility, and elasticity along with the ability to selectively 
exclude a small molecule like an ion but not water make this peptide bilayer an interesting option 
for filtration. With almost 800 million people globally without access to drinking water, 
improved filtration is necessary to ensure availability to clean, fresh water for everyone now and 
in the future.50,51  One method that is being investigated is the purification of salt water and 
brackish water to drinking water. Typically, in order to desalinate sea water, a reverse osmosis 
(RO) procedure or a traditional distillation procedure is used. These techniques typically use a 
great deal of energy to remove ions and contaminants from the water.52 The membranes that are 
used for RO can also be adversely effected or ruined by the pH levels or levels of certain ions, 
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like chloride, in the water they are purifying. In contrast, the BAPC membrane seems to be more 
robust and does not seem to be affected by pH changes or any of the ions that it has been 
exposed to.53  
Forward osmosis (FO) has become more popular in recent years due to the smaller 
amount of energy used and the use of osmotic pressure to pull water through a membrane.54 This 
technology is especially important in areas where there is not sufficient power to run 
desalinization via RO. In these cases, FO stands to be a promising technology to allow access to 
drinking water.54 The use of FO membranes has been shown to be very efficient in removing 
many salts and organic compounds, but it has been difficult to make or find other selectively 
permeable membranes to remove small ions, molecules or organic compounds.55  
The use of peptides and other polymers have begun to be investigated for use in filtration, 
along with the use of nanocapsules as an option for use in FO technology.52,50,54 Because of their 
chemical synthesis and availability of attachment sites for other molecules, these peptide 
surfaces can be easily modified to allow for decreased fouling and unwanted attachment to the 
filter layer.56 The hydrophilic residues already on the external portion of the membrane would 
have a lower chance of fouling from organic compounds. This is due to the hydrogen bonding 
between the water and the filter surface which prevents adsorption between membrane and 
organic compounds.57 The peptides that form the bilayer itself are very stable and would be 
straightforward to scale up to make an appropriately sized bilayer for filtration.53 A planar 
bilayer that mimics the already known bilayer seen in this nanocapsule could be developed from 
these peptide sequences. There is potential in the future that this bilayer may prevent some of 
these drawbacks currently seen with FO. 
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Another option for the BAPCs would the concentration or purification of other 
compounds. One type of compound of great interest to purify is pharmaceuticals. Many of the 
therapeutic agents are pH, temperature, or pressure labile so there aren’t many options to purify 
them that would still keep the compound active.58 The BAPC bilayer can be used at many 
different temperatures and pH values without losing efficacy or membrane stability. This peptide 
bilayer makes a desirable membrane because of its ability to retain salt yet move water and 
remain resistant to many conditions that would destroy other membrane systems.58 
As was previously known from earlier CD data, there are temperature-induced changes in 
the secondary structure of the peptides, and these changes can be seen in the initial curves of 
each of the data sets. The addition of random coil characteristics can be seen in the locked BAPC 
spectra (Figure 2.11) as compared to the room temperature BAPCs (Figure 2.6). Once the 
BAPCs are added to the saline solutions, the locked and room temperature BAPCs both change 
irreversibly to more of a β-sheet structure. Surprisingly, whether the BAPCs are locked or room 
temperature, when they are exposed to NaCl, they both behave the same and seem to become 
more ordered.  
This increase in order of the peptide secondary structure seems to show that the NaCl 
ions behave as a kosmotrope, or an order-inducer, which is consistent with previously published 
data about these ions.59,60 It could be that the charges of the ions decrease the repulsion of the 
positively charged head groups of the lysine residues.59 It could also be that both sodium and 
chloride have a relatively strong interaction with water. Having this strong interaction with water 
is another property that causes them behave as a kosmotrope.61 With these ions present in the 
water at the concentrations used in this work, the polar water molecules are affected, which can 
change the interaction of the solvent with the residues of the BAPCs. This rearrangement of 
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water to a more ordered state due to intermolecular hydrogen bonding may also allow for greater 
expansion and contraction of the water itself. This may lend itself to enhancing the elasticity of 
the BAPC.60 If these ions are present during the self-assembly process of the BAPC, they could 
increase the hydrophobic interactions between the tails of the peptides. This increased 
aggregation of the tails could also increase order and stability of the BAPC.62 
Another potential reason that the BAPCs can contract and change into a more organized 
structure in the presence of NaCl is the displacement of the TFA salt present on the BAPCs. TFA 
is present on the peptides from the cleavage solution that liberates the peptide from the resin. 
Earlier work showed a strong signal from the TFA using 19F NMR. It is possible to replace the 
large TFA molecule on the peptide with the smaller chloride ion using HCl.63 It could also be 
possible that the TFA present on the peptides can also be displaced with moderate to high 
concentrations of Cl-. This less bulky and less hydrophobic molecule acting as a counter-ion on 
the positive charges of the lysine residues could allow for more contractility, flexibility, and 
ordering of the BAPC bilayer. 
 These methods for size approximation and size changes do have their disadvantages and 
problems. As was discussed previously, Figure 2.9 and Figure 2.10 seem to contradict each 
other somewhat. When the locked BAPCs are moved back into water after being in saline 
solutions, the fluorescence is expected to increase some as seen with the raw fluorescence values 
in Figure 2.10, but the corrected percent fluorescence continues to decrease (Figure 2.9). Unlike 
the raw data, the decrease in fluorescence suggests that water continues to move out of the 
BAPCs. This discrepancy brings to light potential issues with only using Eosin Y or Rhodamine 
6G as our gauge for size changes.  
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Future Work 
As mentioned in the previous section, further information is needed to ensure that the 
data obtained from the fluorescence readings accurately describes the behavior of the BAPCs in 
these saline solutions. One method that has been used with BAPCs in the past is dynamic light 
scattering (DLS). DLS has the advantage in this experiment because such experiments are done 
in solution, whether saline or water, and the changes in solution can be monitored as they are 
with Eosin Y BAPCs.  
Because of the physiological relevance of sodium and chloride, these two ions were the 
first chosen for the initial work done with BAPCs and ions. Depending on the physiological 
location, the concentration of ions can fluctuate dramatically. It is important to understand how 
these BAPCs behave when exposed to different ions, both monovalent and divalent, and of 
different sizes, whether it be the hydrated radius or the radius without the attached water 
molecules. It is important to understand how changing the anion or cation affects the BAPCs’ 
behavior, and if it is possible to decrease the stability of the peptides through the use of ions. 
 Publications discussed previously discuss these BAPCs for use as a gene delivery 
vehicle.47,48 When using these as a method for gene delivery, locked BAPCs were used. It has 
been shown how these locked BAPCs behave in the saline solutions, but it is unknown how 
having the plasmid around the external surface of the BAPC affects the expansion or contraction 
of the BAPC. There is the possibility that the DNA may cancel out the positive charges of the 
lysine residues located on the external face of the BAPC and allow for further contraction within 
saline solutions. If the positive charges of the phosphates in the DNA backbone do allow for 
further contraction, it is also necessary to investigate whether this is also true with phosphate in 
solution. This question goes back to the previous statement about the effect of different ions, 
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including differences between monovalent and divalent ions. There may also be saline 
concentrations at which the DNA comes off of the BAPC, and if these are to be used as a gene 
delivery method, knowing when the DNA can be competed off of the BAPCs by salt in solution 
is necessary.  
A paper recently published also brings to light a few more questions regarding the sizing 
of the BAPCs.64 This work discusses the use of variable h5 and h9 ratios to modify the size and 
transfection of the BAPCs. It is clearly seen that the BAPCs made up purely of h9 are much 
smaller than the BAPCs made up purely of h5; the diameters of these are about 10 nm and 45 nm, 
respectively. When using both of these as a transfection agent, the smaller BAPCs consisting of 
pure h9 proved to be the most efficient in delivering DNA to HEK-293 cells.  
This raises a few questions for future work. The BAPCs made up of pure h9 have a 
structure that is mainly β-sheet. This is similar to the BAPCs in saline solutions. The BAPCs in 
saline solutions have shown a propensity to β-sheet structures, which can be suggested that this 
aids in tighter packing and smaller capsules. With the addition of the osmotic pressure on the 
BAPCs, they may get smaller than previously seen. The decrease in size may allow the BAPCs 
to become even more efficient at DNA delivery. It also necessitates looking at the pure h9 
BAPCs in saline solutions. If these are the most relevant BAPCs for future work with these 
capsules, they also need to be thoroughly investigated in the presence of ions. It begs to question 
whether these BAPCs can compress anymore and increase their benefits in the world of research 
and therapeutics. 
The work discussed within this paper only begins to scratch the surface of these unique 
capsules. These BAPCs have the ability to contract, expand, and rearrange the peptides within 
them, all while remaining intact and stable. Size, stability, and ion effects are all necessary 
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aspects to understand fully when hoping to use this in the future as a potential therapeutic or 
delivery vehicle.  
 
 
 
  
50 
References  
 
                                                 
1 Müller, B., & Van de Voorde, M. (Eds.). (2017). Nanoscience and nanotechnology for human 
health. Weinheim, Germany: Wiley-VCH. 
2 Wong, J. K. L., Mohseni, R., Hamidieh, A. A., MacLaren, R. E., Habib, N., & Seifalian, A. M. 
(2017). Will Nanotechnology Bring New Hope for Gene Delivery? Trends in 
Biotechnology, 35(5), 434–451. http://doi.org/10.1016/j.tibtech.2016.12.009 
3 Mishra, B., Patel, B. B., & Tiwari, S. (2010). Colloidal nanocarriers: a review on formulation 
technology, types and applications toward targeted drug delivery. Nanomedicine: 
Nanotechnology, Biology, and Medicine, 6(1), 9–24. 
http://doi.org/10.1016/j.nano.2009.04.008 
4 Henderson, L. A. (2016). National Institutes of Health: An Introduction to Nanotechnology 
Funded Research in Biology and Medicine, Cheng, H. N., Doemeny, L., Geraci, C. L., & 
Schmidt, D. G. (Eds.) Nanotechnology: Delivering on the promise (Volume 1), (59–66). 
Washington, DC: American Chemical Society. 
5 Mandal, D., Dinda, S., Choudhury, P., & Das, P. K. (2016). Solvent induced morphological 
evolution of cholesterol based glucose tailored amphiphiles: Transformation from vesicles 
to nanoribbons. Langmuir, 32(38), 9780–9789. 
http://doi.org/10.1021/acs.langmuir.6b02165 
6 Sahoo, S. K., Parveen, S., & Panda, J. J. (2007). The present and future of nanotechnology in 
human health care. Nanomedicine: Nanotechnology, Biology, and Medicine, 3(1), 20–31. 
http://doi.org/10.1016/j.nano.2006.11.008 
7 Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature Reviews 
Cancer, 5(3), 161–171. http://doi.org/10.1038/nrc1566 
8 Mo, Z. C., Ren, K., Liu, X., Tang, Z. L., & Yi, G. H. (2016). A high-density lipoprotein-
mediated drug delivery system. Advanced Drug Delivery Reviews, 106, 132–147. 
http://doi.org/10.1016/j.addr.2016.04.030 
9 Barry, M., Pearce, H., Cross, L., Tatullo, M., & Gaharwar, A. K. (2016). Advances in 
Nanotechnology for the Treatment of Osteoporosis. Current Osteoporosis Reports, 14(3), 
87–94. http://doi.org/10.1007/s11914-016-0306-3 
10 Griffin, B. T., Guo, J., Presas, E., Donovan, M. D., Alonso, M. J., & O’Driscoll, C. M. (2016). 
Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of 
nanocarriers containing peptide and protein drugs. Advanced Drug Delivery Reviews, 106, 
367–380. http://doi.org/10.1016/j.addr.2016.06.006 
51 
                                                                                                                                                             
11 Choi, H. S., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Ipe, B. I., Bawendi, M. G., & 
Frangioni, J. V. (2007). Renal clearance of nanoparticles. Nat. Biotechnol., 25(10), 1165–
1170. http://doi.org/10.1038/nbt1340.Renal 
12 Bayford, R., Rademacher, T., Roitt, I., & Wang, S. X. (2017). Emerging applications of 
nanotechnology for diagnosis and therapy of disease: A review. Physiological 
Measurement, 38(8), R183–R203. http://doi.org/10.1088/1361-6579/aa7182 
13 Niu, Z., Tedesco, E., Benetti, F., Mabondzo, A., Montagner, I. M., Marigo, I., Gonzalez-
Touceda, D., Tovar, S., Diéguez, C., Santander-Ortega, M. J., & Alonso, M. J. (2016). 
Rational design of polyarginine nanocapsules intended to help peptides overcoming 
intestinal barriers. Journal of Controlled Release. 
http://doi.org/10.1016/j.jconrel.2017.02.024 
14 Herrmann, I. K., & Rösslein, M. (2016). Personalized medicine: The enabling role of 
nanotechnology. Nanomedicine, 11(1), 1–3. http://doi.org/10.2217/nnm.15.152 
15 Azzawi, M., Seifalian, A., & Ahmed, W. (2016). Nanotechnology for the diagnosis and 
treatment of diseases. Nanomedicine, 11(16), 2025–2027. http://doi.org/10.2217/nnm-2016-
8000 
16 Lollo, G., Gonzalez-Paredes, A., Garcia-Fuentes, M., Calvo, P., Torres, D., & Alonso, M. J. 
(2017). Polyarginine nanocapsules as a potential oral peptide delivery carrier. Journal of 
Pharmaceutical Sciences, 106(2), 611–618. http://doi.org/10.1016/j.xphs.2016.09.029 
17 Cui, H., & Chen, X. (2017). Peptides and peptide conjugates in medicine. Advanced Drug 
Delivery Reviews, 110–111, 1–2. http://doi.org/10.1016/j.addr.2017.04.004 
18 Acar, H., Srivastava, S., Chung, E. J., Schnorenberg, M. R., Barrett, J. C., LaBelle, J. L., & 
Tirrell, M. (2017). Self-assembling peptide-based building blocks in medical applications. 
Advanced Drug Delivery Reviews, 110–111, 65–79. 
http://doi.org/10.1016/j.addr.2016.08.006 
19 Sun, X., Li, Y., Liu, T., Li, Z., Zhang, X., & Chen, X. (2017). Peptide-based imaging agents 
for cancer detection. Advanced Drug Delivery Reviews, 110–111, 38–51. 
http://doi.org/10.1016/j.addr.2016.06.007 
20 Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., Stewart, M. H., 
& Medintz, I. L. (2013). Functionalizing nanoparticles with biological molecules: 
Developing chemistries that facilitate nanotechnology. Chemical Reviews, 113(3), 
1904−2074. http://doi.org/10.1021/cr300143v 
21 Eskandari, S., Guerin, T., Toth, I., & Stephenson, R. J. (2017). Recent advances in self-
assembled peptides: Implications for targeted drug delivery and vaccine engineering. 
52 
                                                                                                                                                             
Advanced Drug Delivery Reviews, 110–111, 169–187. 
http://doi.org/10.1016/j.addr.2016.06.013 
22 Ruoslahti, E. (2017). Tumor penetrating peptides for improved drug delivery. Advanced Drug 
Delivery Reviews, 110–111, 3–12. http://doi.org/10.1016/j.addr.2016.03.008 
23 Kuang, H., Ku, S. H., & Kokkoli, E. (2017). The design of peptide-amphiphiles as functional 
ligands for liposomal anticancer drug and gene delivery. Advanced Drug Delivery Reviews, 
110–111, 80–101. http://doi.org/10.1016/j.addr.2016.08.005 
24 Brezaniova, I., Hruby, M., Kralova, J., Kral, V., Cernochova, Z., Cernoch, P., Slouf, M., 
Kredatusova, J., & Stepanek, P. (2016). Temoporfin-loaded 1-tetradecanol-based 
thermoresponsive solid lipid nanoparticles for photodynamic therapy. Journal of Controlled 
Release, 241, 34–44. http://doi.org/10.1016/j.jconrel.2016.09.009 
25 Peyret, A., Ibarboure, E., Pippa, N., & Lecommandoux, S. (2017). Liposomes in 
polymersomes: Multicompartment system with temperature-triggered release, Langmuir, 
33, 7079-7085. http://doi.org/10.1021/acs.langmuir.7b00655 
26 Randles, E. G., & Bergethon, P. R. (2013). A photodependent switch of liposome stability and 
permeability. Langmuir, 29(5), 1490–1497. http://doi.org/10.1021/la303526k 
27 Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming 
biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. 
http://doi.org/10.1038/nbt.3330 
28 Gharpure, K. M., Wu, S. Y., Li, C., Lopez-Berestein, G., & Sood, A. K. (2015). 
Nanotechnology: Future of Oncotherapy. Clinical Cancer Research, 21(14), 3121–3130. 
http://doi.org/10.1158/1078-0432.CCR-14-1189 
29 Le Garrec, D., Ranger, M., & Leroux, J.-C. (2004). Micelles in anticancer drug delivery. 
American Journal of Drug Delivery, 2(1), 15–42. http://doi.org/10.2165/00137696-
200402010-00002 
30 Niu, D., Li, Y., & Shi, J. (2017). Silica/organosilica cross-linked block copolymer micelles: A 
versatile theranostic platform. Chem. Soc. Rev., 46(3), 569–585. 
http://doi.org/10.1039/C6CS00495D 
31 Zuo, Y., Kong, M., Mu, Y., Feng, C., & Chen, X. (2017). Chitosan based nanogels stepwise 
response to intracellular delivery kinetics for enhanced delivery of doxorubicin. 
International Journal of Biological Macromolecules, 104, 157–164. 
http://doi.org/10.1016/j.ijbiomac.2017.06.020 
53 
                                                                                                                                                             
32 Liu, R., Li, X., Xiao, W., & Lam, K. S. (2017). Tumor-targeting peptides from combinatorial 
libraries. Advanced Drug Delivery Reviews, 110–111, 13–37. 
http://doi.org/10.1016/j.addr.2016.05.009 
33 Rajagopal, K., & Schneider, J. P. (2004). Self-assembling peptides and proteins for 
nanotechnological applications. Current Opinion in Structural Biology, 14(4), 480–486. 
http://doi.org/10.1016/j.sbi.2004.06.006 
34 Gonzalez-Paredes, A., Torres, D., & Alonso, M. J. (2017). Polyarginine nanocapsules: A 
versatile nanocarrier with potential in transmucosal drug delivery. International Journal of 
Pharmaceutics. http://doi.org/10.1016/j.ijpharm.2017.07.001 
35 Min, K. I., Yun, G., Jang, Y., Kim, K. R., Ko, Y. H., Jang, H. S., Lee, Y. S., Kim, K., & Kim, 
D. P. (2016). Covalent self-assembly and one-step photocrosslinking of tyrosine-rich 
oligopeptides to form diverse nanostructures. Angewandte Chemie - International Edition, 
128, 7039-7042. http://doi.org/10.1002/anie.201601675 
36 Liu, Y., Liu, C. Y., & Liu, Y. (2011). Investigation on fluorescence quenching of dyes by 
graphite oxide and graphene. Applied Surface Science, 257(13), 5513–5518. 
http://doi.org/10.1016/j.apsusc.2010.12.136 
37 Wang, Y., Lomakin, A., Kanai, S., Alex, R., Belli, S., Donzelli, M., & Benedek, G. B. (2016). 
The molecular basis for the prolonged blood circulation of lipidated incretin peptides: 
Peptide oligomerization or binding to serum albumin? Journal of Controlled Release, 241, 
25–33. http://doi.org/10.1016/j.jconrel.2016.08.035 
38 Ruttala, H. B., Ramasamy, T., Shin, B. S., Choi, H. G., Yong, C. S., & Kim, J. O. (2017). 
Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic 
performance of nanoparticle albumin-bound paclitaxel. International Journal of 
Pharmaceutics, 519(1–2), 11–21. http://doi.org/10.1016/j.ijpharm.2017.01.011 
39 Lehto, T., Ezzat, K., Wood, M. J. A., & Andaloussi, S. EL. (2016). Peptides for nucleic acid 
delivery. Advanced Drug Delivery Reviews, 106(2016), 172–182. 
http://doi.org/10.1016/j.addr.2016.06.008 
40 Englert, C., Trützschler, A. K., Raasch, M., Bus, T., Borchers, P., Mosig, A. S., Traeger, A., & 
Schubert, U. S. (2016). Crossing the blood-brain barrier: Glutathione-conjugated 
poly(ethylene imine) for gene delivery. Journal of Controlled Release, 241, 1–14. 
http://doi.org/10.1016/j.jconrel.2016.08.039 
41 Gudlur, S., Sukthankar, P., Gao, J., Avila, L. A., Hiromasa, Y., Chen, J., Iwamoto, T., & 
Tomich, J. M. (2012). Peptide nanovesicles formed by the self-assembly of branched 
amphiphilic peptides. PLoS ONE, 7(9). http://doi.org/10.1371/journal.pone.0045374 
54 
                                                                                                                                                             
42 Sukthankar, P., Gudlur, S., Avila, L. A., Whitaker, S. K., Katz, B. B., Hiromasa, Y., Gao, J., 
Thapa, P., Moore, D., Iwamoto, T., Chen, J., & Tomich, J. M. (2013). Branched 
oligopeptides form nanocapsules with lipid vesicle characteristics. Langmuir, 29, 14648–
14654. http://doi.org/10.1021/la403492n 
43 Sukthankar, P., Whitaker, S. K., Garcia, M., Herrera, A., Boatwright, M., Prakash, O., & 
Tomich, J. M. (2015). Thermally induced conformational transitions in nascent branched 
amphiphilic peptide capsules. Langmuir, 31(10), 2946–2955. 
http://doi.org/10.1021/la504381y 
44 Sukthankar, P., Avila, L. A., Whitaker, S. K., Iwamoto, T., Morgenstern, A., Apostolidis, C., 
Liu, K., Hanzlik, R. P., Dadachova, E., & Tomich, J. M. (2014). Branched amphiphilic 
peptide capsules: Cellular uptake and retention of encapsulated solutes. Biochimica et 
Biophysica Acta - Biomembranes, 1838(9), 2296–2305. 
http://doi.org/10.1016/j.bbamem.2014.02.005 
45 Richard, I., Thibault, M., De Crescenzo, G., Buschmann, M. D., & Lavertu, M. (2013). 
Ionization behavior of chitosan and chitosan-DNA polyplexes indicate that chitosan has a 
similar capability to induce a proton-sponge effect as PEI. Biomacromolecules, 14(6), 
1732–1740. http://doi.org/10.1021/bm4000713 
46 Benjaminsen, R. V, Mattebjerg, M. A., Henriksen, J. R., Moghimi, S. M., & Andresen, T. L. 
(2012). The possible “proton sponge ” effect of polyethylenimine (PEI) does not include 
change in lysosomal pH. Molecular Therapy, 21(1), 149–157. 
http://doi.org/10.1038/mt.2012.185 
47 Avila, L. A., Aps, L. R. M. M., Ploscariu, N., Sukthankar, P., Guo, R., Wilkinson, K. E., 
Games, P., Szoszkiewicz, R., Alves, R. P. S., Diniz, M. O., Fang, Y., Ferreira, L. C. S. & 
Tomich, J. M. (2016). Gene delivery and immunomodulatory effects of plasmid DNA 
associated with branched amphiphilic peptide capsules. Journal of Controlled Release, 241, 
15–24. http://doi.org/10.1016/j.jconrel.2016.08.042 
48 Avila, L. A., Aps, L. R. M. M., Sukthankar, P., Ploscariu, N., Gudlur, S., Šimo, L., 
Szoszkiewicz, R., Park, Y., Lee, S. Y., Iwamoto, T., Ferreira, L. C. S., & Tomich, J. M. 
(2015). Branched amphiphilic cationic oligo-peptides form peptiplexes with DNA: A study 
of their biophysical properties and transfection efficiency. Molecular Pharmaceutics. 
http://doi.org/10.1021/mp500524s 
49 Jia, Z., Whitaker, S. K., Tomich, J. M., & Chen, J. (2016). Organization and structure of 
branched amphipathic oligopeptide bilayers. Langmuir, 32(38), 9883–9891. 
http://doi.org/10.1021/acs.langmuir.6b02421 
50 Wang, J., Dlamini, D. S., Mishra, A. K., Theresa, M., Pendergast, M., Wong, M. C. Y., 
Mamba, B. B., Freger, V., Verliefde, A. R. D., & Hoek, E. M. V. (2014). A critical review 
55 
                                                                                                                                                             
of transport through osmotic membranes. Journal of Membrane Science, 454, 516–537. 
http://doi.org/10.1016/j.memsci.2013.12.034 
51 Lee, K. P., Arnot, T. C., & Mattia, D. (2011). A review of reverse osmosis membrane 
materials for desalination — Development to date and future potential. Journal of 
Membrane Science, 370, 1–22. http://doi.org/10.1016/j.memsci.2010.12.036 
52 Emadzadeh, D., Lau, W. J., Matsuura, T., Rahbari-Sisakht, M., & Ismail, A. F. (2014). A 
novel thin film composite forward osmosis membrane prepared from PSf-TiO2 
nanocomposite substrate for water desalination. Chemical Engineering Journal, 237, 70–80. 
http://doi.org/10.1016/j.cej.2013.09.081 
53 Li, D., Yan, Y., & Wang, H. (2016). Recent advances in polymer and polymer composite 
membranes for reverse and forward osmosis processes. Progress in Polymer Science, 61, 
104–155. http://doi.org/10.1016/j.progpolymsci.2016.03.003 
54 Emadzadeh, D., Lau, W. J., Matsuura, T., Ismail, A. F., & Rahbari-Sisakht, M. (2014). 
Synthesis and characterization of thin film nanocomposite forward osmosis membrane with 
hydrophilic nanocomposite support to reduce internal concentration polarization. Journal of 
Membrane Science, 449, 74–85. http://doi.org/10.1016/j.memsci.2013.08.014 
55 Chen, L., Gu, Y., Cao, C., Zhang, J., Ng, J. W., & Tang, C. (2014). Performance of a 
submerged anaerobic membrane bioreactor with forward osmosis membrane for low-
strength wastewater treatment. Water Research, 50, 114–123. 
http://doi.org/10.1016/j.watres.2013.12.009 
56 Ulbricht, M. (2006). Advanced functional polymer membranes. Polymer, 47(7), 2217–2262. 
http://doi.org/10.1016/j.polymer.2006.01.084 
57 Lalia, S. B., Kochkodan, V., Hashaikeh, R., & Hilal, N. (2013). A review on membrane 
fabrication : Structure, properties and performance relationship. Desalination, 326, 77–95. 
http://doi.org/10.1016/j.desal.2013.06.016 
58 Chung, T.-S., Zhang, S., Wang, K. Y., Su, J., & Ling, M. M. (2011). Forward osmosis 
processes: Yesterday, today and tomorrow. Desalination, 287, 78–81. 
http://doi.org/10.1016/j.desal.2010.12.019 
59 Akpinar, E., Turkmen, M., Canioz, C., & Neto, A. M. F. (2016). Role of kosmotrope-
chaotrope interactions at micelle surfaces on the stabilization of lyotropic nematic phases. 
The European Physical JournaL E, 39(107). http://doi.org/10.1140/epje/i2016-16107-5 
60 Khan, S. H., Kramkowski, E. L., & Hoffmann, P. M. (2016). NaCl-Dependent ordering and 
dynamic mechanical response in nanoconfined water. Langmuir, 32, 10802-10807. 
http://doi.org/10.1021/acs.langmuir.6b02535 
56 
                                                                                                                                                             
61 Liu, L., Kou, R., & Liu, G. (2016). Ion specificities of artificial macromolecules. Soft Matter, 
13, 68–80. http://doi.org/10.1039/c6sm01773h 
62 Moelbert, S., Normand, B., & Rios, P. D. L. (2004). Kosmotropes and chaotropes : Modelling 
preferential exclusion, binding and aggregate stability, Biophysical Chemistry, 112, 45–57. 
http://doi.org/10.1016/j.bpc.2004.06.012 
63 Andrushcchenko, V. V., Vogel, H. J., & Prenner, E. J. (2007). Optimization of the 
hydrochloric acid concentration used for trifluoroacetate removal from synthetic peptides. 
Journal of Peptide Science, 13, 37-43. http://doi.org/10.1002/psc.793 
64 Barros, S. D. M., Avila, L. A., Whitaker, S. K., Wilkinson, K. E., Sukthankar, P., Beltra, E. I. 
C., & Tomich, J. M. (2017). Branched Amphipathic Peptide Capsules: Different ratios of 
the two constituent peptides direct distinct bilayer structures, sizes, and DNA transfection 
efficiency. Langmuir, 33, 7096 – 7104. http://doi.org/10.1021/acs.langmuir.7b00912 
 
 
 
 
 
 
 
  
57 
Appendix A – Copyright Permissions 
 
58 
 
 
